Why Insulet’s recent device correction and mixed sentiment matter for investors

Insulet (PODD) is back in focus after a voluntary Medical Device Correction for certain Omnipod 5 pod lots, mixed analyst reactions, and louder commentary about GLP-1 competition and future growth potential.

Recent headlines, including the Omnipod 5 device correction, mixed commentary on GLP-1 competition, and updated earnings guidance, have coincided with weaker momentum, with a 30-day share price return of 8.96% and a 1-year total shareholder return of 26.96%.

If this mix of risk and opportunity has your attention, it could be a good moment to widen your search and check out 33 healthcare AI stocks

After a year where Insulet shares have lagged, with a 1 year total return of 26.96% turning into a 1 year decline of 26.96% in the latest data, the key question is clear: is this reset an opportunity, or is the market already pricing in every dollar of future growth?

Most Popular Narrative: 41.9% Undervalued

With Insulet last closing at $189.56 and the most followed narrative pointing to a fair value of $326.35, the gap between price and modeled value is wide enough to make the underlying growth assumptions worth a closer look.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Curious what kind of revenue ramp, margin lift, and future earnings multiple underpin that valuation gap? The narrative leans on compounding growth, expanding profitability, and a premium P/E that depends on those projections holding up.

Result: Fair Value of $326.35 (UNDERVALUED)

However, that upside case hinges on Omnipod staying ahead of rising patch pump competition and on recent device correction issues not denting confidence in the platform or margins.

Another way to look at Insulet’s valuation

The first narrative leans heavily on future cash flows and growth to argue Insulet is undervalued. The market today is telling a different story, with a P/E of 53.1x compared with a fair ratio of 30.6x, the US Medical Equipment industry at 25.1x, and peers at 37.6x. That premium suggests investors are already paying up for strong execution. The question is whether you think the story justifies staying above those reference points.

Next Steps

On balance, the story here is mixed, with clear concerns and clear optimism. Move quickly, review the underlying data, and weigh Insulet on its own terms by checking the 2 key rewards and 2 important warning signs

Ready to widen your opportunity set?

If Insulet is on your radar, do not stop there. Use the Simply Wall Street Screener to quickly surface other ideas that fit what you care about most.

• Target potential mispricing by scanning for companies that look cheap relative to quality through the 54 high quality undervalued stocks
• Prioritize resilience and sleep better at night by focusing on businesses highlighted in the 72 resilient stocks with low risk scores
• Hunt for future leaders before they are widely followed by checking the screener containing 25 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.